Zolgensma data show rapid onset of response for SMA type 2

As Novartis awaits an FDA decision any day on its spinal muscular atrophy gene therapy Zolgensma, data presented over the weekend at AAN suggest that at least half of patients could see a benefit within the first month of treatment, giving it an edge over marketed SMA therapy Spinraza nusinersen.

The AveXis Inc. unit of Novartis AG (NYSE:NVS; SIX:NOVN) presented the first data for Zolgensma onasemnogene abeparvovec-xioi (AVXS-101) in patients with late-onset SMA known as SMA

Read the full 750 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE